Vaxart Resolves Proxy Contest with Activist Shareholders, Agrees to Board Seat and Governance Changes

summarizeSummary

Vaxart has reached a cooperation agreement with activist shareholders, ending a proxy contest and agreeing to appoint a new director, restructure board committees, and implement new governance policies.

check_boxKey Events · Corporate Governance and Compliance · VXRT

• Proxy Contest Resolved

  The activist group "Concerned Vaxart Stockholders" withdrew their slate of director nominees for the 2026 Annual Meeting, ending the proxy contest.

• Cooperation Agreement Reached

  Vaxart entered into a cooperation agreement with the activist group, formalizing the resolution of the proxy contest.

• New Director Appointment

  The Board agreed to identify and appoint a new director within 60-90 days of the 2026 Annual Meeting, who will also join the Nominating and Governance Committee and chair a new Stockholder Engagement Committee.

• Board Committee Restructuring

  The Board will determine new compositions and chairs for the Nominating and Governance and Compensation Committees, and form a new Clinical and Regulatory Affairs Committee.

auto_awesomeAnalysis · VXRT · Life Sciences

This filing marks the resolution of a contentious proxy contest initiated by the "Concerned Vaxart Stockholders." The cooperation agreement brings stability by ending the dispute but also introduces significant governance changes. The company will appoint a new director, who will also chair a new Stockholder Engagement Committee, and will form a Clinical and Regulatory Affairs Committee. These changes indicate a shift in board composition and oversight, potentially addressing shareholder concerns about strategic direction and clinical development, especially following the company's recent financial turnaround.